# US 2010/0168225 A1 · Small-Molecule Hepatitis C Virus (HCV) NS3/4A Serine Protease Inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168225 A1
- Document ID: US20100168225A1
- Status: Published application
- Kind: A1
- Application number: 12/594,790
- Filed: 2008-04-18
- Published: 2010-07-01
- Earliest claimed: 2007-04-18
- Inventors: Francois Jean; Raymond Andersen
- Web page: https://patentgrep.com/patent/US20100168225A1

## CPC

- C07D 311/16: substituted in position 7
- A61P 31/14: for RNA viruses
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds of Formula 5 and prodrug compounds of Formula 5 wherein G1 is H or OH; G2 is H, R′, or CO2R′; G3, G4 and G5, are each independently selected from the group consisting of: H, R′, OH, OR′, F, Cl, Br, I, NH2, NHR′,NR′2, CN, SH, SR′, SO3H, SO3R′, SO2R′, OSO3R′, and NO2; and R′ is a one to four carbon alkyl group are provided. Uses of these compounds and methods of medical treatment involving these compounds for the treatment of hepatitis C are also provided.

## Claims

### Claim 1

A prodrug compound of Formula 5:
wherein
G1 is H or OH;
G2 is H, R′, or CO2R′;
G3, G4 and G5, are each independently selected from the group consisting of: H, R′, OH, OR′, F, Cl, Br, I, NH2, NHR′, NR′2, CN, SH, SR′, SO3H, SO3R′, SO2R′, OSO3R′, and NO2;
each R′ is independently a one to four carbon alkyl group; and
from 1 to 5 OH moieties are replaced with a prodrug moiety.

### Claim 2 (depends on 1)

The prodrug compound of claim 1 wherein G1 is OH or a prodrug moiety.

### Claim 3 (depends on 1, 2)

The prodrug compound of claim 1 or 2 wherein G1 is OH and not a prodrug moiety.

### Claim 4 (depends on 1, 2, 3)

The prodrug compound of any one of claims 1 to 3 wherein each R′ is independently selected from the group consisting of: methyl and ethyl.

### Claim 5 (depends on 1, 2, 3, 4)

The prodrug compound of any one of claims 1 to 4 wherein G2 is selected from the group consisting of: H, Me, Et, CO2Me, and CO2Et.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The prodrug compound of any one of claims 1 to 5 wherein G3 is H.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The prodrug compound of any one of claims 1 to 6 wherein G4 and G5 are independently H, OH or a prodrug moiety and at least one of G4 and G5 is OH or a prodrug moiety.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The prodrug compound of any one of claims 1 to 7 wherein G4 and G5 are independently H, or OH and not a prodrug moiety and at least one of G4 and G5 is OH and not a prodrug moiety.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The prodrug compound of any one of claims 1 to 8 wherein the prodrug moiety is an ester prodrug moiety.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The prodrug compound of any one of claims 1 to 8 wherein the prodrug moiety is a 1 to 6 carbon alkyl-ester moiety.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The prodrug compound of any one of claims 1 to 8 wherein the prodrug moiety is not a 1 to 6 carbon alkyl-ester moiety.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The prodrug compound of any one of claims 1 to 11 for use in the treatment of hepatitis C.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

Use of the prodrug compound of any one of claims 1 to 11 for the treatment of hepatitis C.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

Use of the prodrug compound of any one of claims 1 to 11 for the preparation of a medicament for the treatment of hepatitis C.

### Claim 15

Use of a compound of Formula 5:
wherein
G1 is H or OH;
G2 is H, R′, or CO2R;
G3, G4 and G5 are each independently selected from the group consisting of: H, R′, OH, OR′, F, Cl, Br, I, NH2, NHR′, NR′2, CN, SH, SR′, SO3H, SO3R′, SO2R′, OSO3R′, and NO2; and
R′ is a one to four carbon alkyl group,
for treatment of hepatitis C.

### Claim 16

Use of a compound of Formula 5:
wherein
G1 is H or OH;
G2 is H, R′, or CO2R;
G3, G4 and G5 are each independently selected from the group consisting of: H, R′, OH, OR′, F, Cl, Br, I, NH2, NHR′, NR′2, CN, SH, SR′, SO3H, SO3R′, SO2R′, OSO3R′, and NO2; and
R′ is a one to four carbon alkyl group,
for preparation of a medicament for treatment of hepatitis C.

### Claim 17 (depends on 15, 16)

The use of claim 15 or 16 wherein G1 is OH.

### Claim 18 (depends on 15, 16, 17)

The use of any one of claims 15 to 17 wherein R′ is selected from the group consisting of: methyl and ethyl.

### Claim 19 (depends on 15, 16, 17, 18)

The use of any one of claims 15 to 18 wherein G2 is selected from the group consisting of: H, Me, Et, CO2Me, and CO2Et.

### Claim 20 (depends on 15, 16, 17, 18, 19)

The use of any one of claims 15 to 19 wherein G3 is H.

### Claim 21 (depends on 15, 16, 17, 18, 19, 20)

The use of any one of claims 15 to 20 wherein G4 and G5 are independently H or OH, and at least one of G4 and G5 is OH.

### Claim 22

Use of a compound having the structure:
for the treatment of hepatitis C.

### Claim 23

Use of a compound having the structure:
for the preparation of a medicament for the treatment of hepatitis C.

### Claim 24

Use of a compound having the structure:
for the treatment of hepatitis C.

### Claim 25

Use of a compound having the structure:
for the preparation of a medicament for the treatment of hepatitis C.

### Claim 26

Use of a compound having the structure:
for the treatment of hepatitis C.

### Claim 27

Use of a compound having the structure:
for the preparation of a medicament for the treatment of hepatitis C.

### Claim 28

Use of a compound having the structure:
for the treatment of hepatitis C.

### Claim 29

Use of a compound having the structure:
for the preparation of a medicament for the treatment of hepatitis C.

### Claim 30

Use of a compound having the structure:
for the treatment of hepatitis C.

### Claim 31

Use of a compound having the structure:
for the preparation of a medicament for the treatment of hepatitis C.

### Claim 32

Use of a compound having the structure:
for the treatment of hepatitis C.

### Claim 33

Use of a compound having the structure:
for the preparation of a medicament for the treatment of hepatitis C.

### Claim 34

Use of a compound having the structure:
for the treatment of hepatitis C.

### Claim 35

Use of a compound having the structure:
for the preparation of a medicament for the treatment of hepatitis C.

### Claim 36 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The use of any one of claims 22 to 35 wherein any one or more OH moieties is replaced with a prodrug moiety.

### Claim 37 (depends on 36)

The use of claim 36 wherein the prodrug moiety is an ester prodrug moiety.

### Claim 38 (depends on 36, 37)

The use of claim 36 or 37 wherein the prodrug moiety is a 1 to 6 carbon alkyl-ester moiety.

### Claim 39 (depends on 36, 37)

The use of claim 36 or 37 wherein the prodrug moiety is not a 1 to 6 carbon alkyl-ester moiety.

### Claim 40

A method for treating hepatitis C comprising administering a therapeutically effective amount of a compound of Formula 5 or a prodrug compound of Formula 5:
wherein
G1 is H, or OH;
G2 is H, R′, or CO2R′;
G3, G4 and G5, are each independently selected from the group consisting of: H, R′, OH, OR′, F, Cl, Br, I, NH2, NHR′, NR′2, CN, SH, SR′, SO3H, SO3R′, SO2R′, OSO3R′, and NO2;
R′ is a one to four carbon alkyl group; and
from 0 to 5 OH moieties are replaced with a prodrug moiety,
to a subject in need thereof.

### Claim 41 (depends on 40)

The method of claim 40 wherein G1 is OH or a prodrug moiety.

### Claim 42 (depends on 40, 41)

The method of claim 40 or 41 wherein G1 is OH and not a prodrug moiety.

### Claim 43 (depends on 40, 41, 42)

The method of any one of claims 40 to 42 wherein R′ is selected from the group consisting of: methyl and ethyl.

### Claim 44 (depends on 40, 41, 42, 43)

The method of any one of claims 40 to 43 wherein G2 is selected from the group consisting of: H, Me, Et, CO2Me, and CO2Et.

### Claim 45 (depends on 40, 41, 42, 43, 44)

The method of any one of claims 40 to 44 wherein G3 is H.

### Claim 46 (depends on 40, 41, 42, 43, 44, 45)

The method of any one of claims 40 to 45 wherein G4 and G5 are independently H, OH or a prodrug moiety and at least one of G4 and G5 is OH or a prodrug moiety.

### Claim 47 (depends on 40, 41, 42, 43, 44, 45, 46)

The method of any one of claims 40 to 46 wherein G4 and G5 are independently H or OH and not a prodrug moiety and at least one of G4 and G5 is OH and not a prodrug moiety.

### Claim 48 (depends on 40, 41, 42, 43, 44, 45, 46, 47)

The method of any one of claims 40 to 47 wherein the prodrug moiety is an ester prodrug moiety.

### Claim 49 (depends on 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

The method of any one of claims 40 to 58 wherein the prodrug moiety is a 1 to 6 carbon alkyl-ester moiety.

### Claim 50 (depends on 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

The method of any one of claims 40 to 58 wherein the prodrug moiety is not a 1 to 6 carbon alkyl-ester moiety.

### Claim 51

A method for treating hepatitis C comprising administering a therapeutically effective amount of a compound having the structure:
to a subject in need thereof.

### Claim 52

A method for treating hepatitis C comprising administering a therapeutically effective amount of a compound having the structure:
to a subject in need thereof.

### Claim 53

A method for treating hepatitis C comprising administering a therapeutically effective amount of a compound having the structure:
to a subject in need thereof.

### Claim 54

A method for treating hepatitis C comprising administering a therapeutically effective amount of a compound having the structure:
to a subject in need thereof.

### Claim 55

A method for treating hepatitis C comprising administering a therapeutically effective amount of a compound having the structure:
to a subject in need thereof.

### Claim 56

A method for treating hepatitis C comprising administering a therapeutically effective amount of a compound having the structure:
to a subject in need thereof.

### Claim 57

A method for treating hepatitis C comprising administering a therapeutically effective amount of a compound having the structure:
to a subject in need thereof.

### Claim 58 (depends on 51, 52, 53, 54, 55, 56, 57)

The method of any one of claims 51 to 57 wherein any one or more OH moieties is replaced with a prodrug moiety.

### Claim 59 (depends on 58)

The method of claim 58 wherein the prodrug moiety is an ester prodrug moiety.

### Claim 60 (depends on 58, 59)

The method of claim 58 or 59 wherein the prodrug moiety is a 1 to 6 carbon alkyl-ester moiety.

### Claim 61 (depends on 58, 59)

The method of claim 58 or 59 wherein the prodrug moiety is not a 1 to 6 carbon alkyl-ester moiety.
